Benitec Biopharma's 15min chart triggered KDJ Golden Cross, Bullish Marubozu Signal

Benitec Biopharma's 15-minute chart has recently triggered a Golden Cross using the KDJ indicator, accompanied by a bullish Marubozu candlestick pattern on September 10, 2025 at 10:15. This suggests that the momentum of the stock price is shifting towards an upward trend and has the potential to continue increasing. The buyers are in control of the market, and it is likely that bullish momentum will persist.

Benitec Biopharma's 15-minute chart has recently exhibited a notable technical indicator that suggests a shift in momentum towards an upward trend. On September 10, 2025, at 10:15, the KDJ Golden Cross was observed, accompanied by a bullish Marubozu candlestick pattern [^NUMBER]. These indicators suggest that the stock's price is likely to continue increasing, with buyers controlling the market and bullish momentum persisting.

The KDJ Golden Cross, generated by the KDJ indicator, occurs when the K line crosses above the D line. This is often seen as a bullish signal, indicating a potential shift in the stock's momentum towards the upside. The Bullish Marubozu, characterized by a long body with no shadows above or below, suggests that the stock is being driven by strong buying pressure.

While these technical indicators provide valuable insights into the potential direction of Benitec Biopharma's stock price, investors should consider them in conjunction with fundamental analysis and broader market conditions. Benitec Biopharma has demonstrated strong financial health and shareholder commitment through its recent dividend hike and consistent earnings growth.

Several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts. For example, Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00. Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00. CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00. Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating. Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00. Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside. Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00. Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00. JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating. Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen. Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup. MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating. Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00. Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00. Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target. Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target. Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00. Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00. Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00. Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target. PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank. Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00.